The Oncomap™ ExTra test provides treating physicians with vital information to understand changes to a patient’s genomic profile. Knowing this information can provide a more complete biological picture of certain refractory, rare, or aggressive cancers, helping patients and physicians make informed choices when considering therapeutic treatment plans.

Primarily used by physicians, academic medical centers, and biopharma researchers, the Oncomap™ ExTra test is a comprehensive sequencing test, including both genomic (DNA) and transcriptomic (RNA) panels, and approximately 20,000 genes and 169 introns.1  


1Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):283ra53. doi:10.1126/scitranslmed.aaa7161